Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1992822 | 0.89 | KMT2A (0.44) | CYP4F2CYP4A11KMT2AALDH1A1KDM4E | |
| SCHEMBL15896556 | 0.88 | BCL9 (0.42) | BCL9CTNNB1CYP4F2CYP4A11KMT2A | |
| SCHEMBL13228832 | 0.86 | BCL9 (0.55) | BCL9CTNNB1KMT2AALDH1A1KDM4E | |
| SCHEMBL1995725 | 0.84 | CYP4F2 (0.49) | CYP4F2CYP4A11KMT2AALDH1A1KDM4E | |
| SCHEMBL1996079 | 0.83 | BCL9 (0.46) | BCL9CTNNB1KMT2AALDH1A1KDM4E | |
| SCHEMBL6556364 | 0.82 | KMT2A (0.48) | BCL9CTNNB1KMT2AALDH1A1KDM4E | |
| SCHEMBL3127812 | 0.81 | BCL9 (0.60) | BCL9CTNNB1KMT2AALDH1A1KDM4E | |
| SCHEMBL27761332 | 0.80 | BCL9 (0.44) | BCL9CTNNB1KMT2AALDH1A1KDM4E | |
| SCHEMBL4081113 | 0.80 | KMT2A (0.40) | CYP4F2CYP4A11KMT2AKDM4EALOX15 | |
| SCHEMBL27384896 | 0.80 | KMT2A (0.51) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| CN-104112870-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same | MITSUBISHI CHEM CORP | 2014-10-22 | — | — | CN | disclosed |
| CN-102186921-B | Fluorine-containing copolymer composition and process for production thereof | ASAHI GLASS CO LTD | 2014-01-15 | — | — | CN | disclosed |
| US-20130244122-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME | ONUKI MASAMICHI (JP) | 2013-09-19 | — | — | US | disclosed |
| EP-2338935-B1 | FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF | ASAHI GLASS CO LTD (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-20120219866-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2475041-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE BATTERY COMPRISING SAME | Mitsubishi Chemical Corporation (JP) | 2012-07-11 | — | — | EP | disclosed |
| CN-102484281-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same | MITSUBISHI CHEM CORP | 2012-05-30 | — | — | CN | disclosed |
| CN-102186921-A | Fluorine-containing copolymer composition and process for production thereof | ASAHI GLASS CO LTD | 2011-09-14 | — | — | CN | disclosed |
| US-20110172336-A1 | FLUOROCOPOLYMER COMPOSITION AND ITS PRODUCTION PROCESS | ASAHI GLASS COMPANY, LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2338935-A1 | FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF | ASAHI GLASS COMPANY, LIMITED (JP) | 2011-06-29 | — | — | EP | disclosed |
| US-7741316-B2 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2010-06-22 | — | — | US | disclosed |
| US-20050130953-A1 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2005-06-16 | — | — | US | disclosed |
| US-6872717-B2 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20030055033-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ACHARD DANIEL (FR) | 2003-03-20 | — | — | US | disclosed |
| US-6479479-B2 | 1-DIARYLMETHYL-4-ALKYL OR ALKYLSULFONYLALKYL-AZETIDINES; CANNABINOID RECEPTOR ANTAGONISTS; NERVOUS SYSTEM DISORDERS (CNS); CARDIOVASCULAR AND GLANDULAR DISORDERS; DRUG ABUSE; PSYCHOLOGICAL DISORDERS; | AVENTIS PHARMA S.A. (FR) | 2002-11-12 | — | — | US | disclosed |
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2001-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | BCL9 96/4885CTNNB1 3227/4885CYP4F2 263/4885 |
| US-20030055033-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | BCL9 96/4885CTNNB1 3227/4885CYP4F2 263/4885 |
| US-20050130953-A1 | Pharmacological uses of azetidine derivatives | CHRM2, ACHE, DRD2 | BCL9 659/4885CTNNB1 4065/4885CYP4F2 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.